secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2026-01-05T23:59:59+00:00
Accession:  0001493152-26-000267
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir-1 reduces tumor growth and metastases in aggressive TNBC models in preclinical study
--------------------------------------------------------------------------------

- Telomir-1 showed statistically significant reductions in primary tumor growth in two of three aggressive TNBC zebrafish xenograft models.
- In a paclitaxel-resistant model, Telomir-1 reduced tumor growth as monotherapy and in combination, and cut cancer cell spread.
- Third model (broadly treatment-resistant, ~15-25% of TNBC) showed no significant effect from Telomir-1 or paclitaxel.
- Responsive models represent ~40-60% of TNBC; company plans patient selection based on tumor biology for future trials.
- Study used BioReperia’s ZTX ONCOLEADS platform; company continues IND-enabling activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226000267/0001493152-26-000267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226000267/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-000267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer